Illustration of time at risk of IMD, MCV4 vaccination uptake and

Download scientific diagram | Illustration of time at risk of IMD, MCV4 vaccination uptake and duration of protection from MCV4 in all cohorts studied. IMD = Invasive meningococcal disease, MCV4 = meningococcal ACWY conjugate vaccine from publication: Cost-effectiveness of meningococcal vaccination of Norwegian teenagers with a quadrivalent ACWY conjugate vaccine | In Norway, the incidence of invasive meningococcal disease (IMD) is higher among 16–19-year-olds than in the general population. Most IMD cases among teenagers are caused by serogroup Y. Since 2011, one dose of meningococcal ACWY conjugate vaccine (MCV4) has been recommended | Meningococcal Vaccines, Conjugate Vaccines and Vaccines | ResearchGate, the professional network for scientists.

Meningococcal carriage in Norwegian teenagers: strain characterisation and assessment of risk factors, Epidemiology & Infection

Epidemiology of serogroup C and Y invasive meningococcal disease (IMD) in Ontario, 2000–2013: Vaccine program impact assessment - ScienceDirect

Meningococcal Vaccines Market Size & Share Report, 2030

Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines. - Abstract - Europe PMC

Meningococcal Disease Outbreaks: A Moving Target and a Case for Routine Preventative Vaccination

Full article: The changing epidemiology of meningococcal disease in North America 1945–2010

WO2018142280A2 - Neisseria meningitidis compositions and methods thereof - Google Patents

Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study

WO2016132294A1 - Neisseria meningitidis compositions and methods thereof - Google Patents

SciELO - Saúde Pública - Impact and effectiveness of meningococcal vaccines: a review Impact and effectiveness of meningococcal vaccines: a review

Illustration of time at risk of IMD, MCV4 vaccination uptake and

Immunogenicity and safety of the meningococcal B recombinant (4CMenB) vaccine in allogeneic hematopoietic cell transplantation recipients - ScienceDirect